Latigo Biotherapeutics, Inc.
For the period ended Jun 30, 2026. Filed Sep 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Sep 3, 2026
LTGO$13.33-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Six months ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(48,758) | $(46,787) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Non-cash lease expense | 281 | 182 |
| Depreciation | 99 | 133 |
| Stock-based compensation expense | 4,121 | 3,152 |
| Change in fair value of preferred stock tranche liability | — | 879 |
| Amortization of debt discount and issuance costs | 275 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 198 | (2,160) |
| Other assets | (3,262) | 266 |
| Accounts payable | (1,449) | (1,448) |
| Accrued expenses and other current liabilities | 441 | 3,255 |
| Operating lease liabilities | (296) | (188) |
| Net cash used in operating activities | (48,350) | (42,716) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (110) | (135) |
| Net cash used in investing activities | (110) | (135) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs paid | — | 99,433 |
| Proceeds from issuance of convertible notes | 35,000 | — |
| Proceeds from issuance of common stock upon exercise of stock options | 231 | — |
| Payment of deferred initial public offering costs | (1,282) | — |
| Net cash provided by financing activities | 33,949 | 99,433 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (14,511) | 56,582 |
| Cash, cash equivalents and restricted cash, beginning of period | 69,721 | 17,918 |
| Cash, cash equivalents and restricted cash, end of period | $55,210 | $74,500 |
| Supplemental cash flow information: | ||
| Right-of-use assets obtained in exchange for operating lease liabilities | $959 | $310 |
| Supplemental disclosure for non-cash investing and financing activities: | ||
| Unpaid deferred initial public offering costs included in accounts payable and accrued liabilities | $2,005 | $— |
| Unpaid convertible notes issuance costs included in accrued expenses and other current liabilities | $168 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.